This study focuses on individuals living with Eosinophilic Asthma, a type of Asthma where the airways are inflamed due to high levels of eosinophils, which are a specific type of white blood cell. The condition being studied is specifically Uncontrolled Moderate to Severe Eosinophilic Asthma, meaning the symptoms are not well-managed by current standard treatments. The purpose of the study is to evaluate the efficacy of different doses of the experimental medication KT-621 compared to a placebo.

Participants in the study will take an oral tablet. Some will receive different doses of KT-621, while others will receive a placebo. To ensure the results are fair, the study is double blind, meaning neither the participants nor the researchers know which specific treatment is being administered at any given time. The study is organized into different groups that receive their assigned medication simultaneously to compare how well the drug works and to monitor its safety profile.